Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Cat. Gr.: STBBI Res.: Beyond HIV/AIDS/Hep. C- STBBI other than HIV/hep. C (gen.)

University of British Columbia

$99,715.00

Designing a novel vaccine against herpes simplex virus 2

FY 2023-24

Summary
Herpes simplex virus 2 (HSV-2) is a sexually transmitted virus that affects over 500 million individuals worldwide. HSV-2 establishes a life-long infection with the host and causes lesions, pain, and discomfort in the female genital tract that persists for life. In addition, HSV-2 infection increases the risk of co-infection by HIV or hepatitis C virus as well as pathogenic bacteria that are responsible for bacterial vaginosis. Although the antiviral drug, acyclovir, is available, acyclovir needs to be taken as a daily five dose regimen for the duration of symptoms and does not prevent recurring symptoms. There are currently no vaccines available to treat HSV-2, in part due to inherent challenges associated with the development of mucosal vaccines. The goal of our project is to design a new vaccine against HSV-2 by combining the advantages of several existing vaccine platforms. We will test the efficacy in mouse models of vaginal HSV-2 infection. As no successful vaccines are available for HSV-2, our work has the potential to ignite new avenues of research in the development of vaccines against HSV-2.
Program
Cat. Gr.: STBBI Res.: Beyond HIV/AIDS/Hep. C- STBBI other than HIV/hep. C (gen.)
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
488762
Name
Tokuyama Maria
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis C (Catalyst)
Projecttitle
Designing a novel vaccine against herpes simplex virus 2
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$99,715
Cihrequipment2
$0
Programname2
Cat. Gr.: STBBI Res.: Beyond HIV/AIDS/Hep. C- STBBI other than HIV/hep. C (gen.)
Keyworddelim
Antiviral Immunity; Endogenous Retroviruses; Epithelial Repair; Female Genital Tract; Mucosal Barrier Integrity; Sexually Transmitted Infections; Vaginal Epithelium
Abstract
Herpes simplex virus 2 (HSV-2) is a sexually transmitted virus that affects over 500 million individuals worldwide. HSV-2 establishes a life-long infection with the host and causes lesions, pain, and discomfort in the female genital tract that persists for life. In addition, HSV-2 infection increases the risk of co-infection by HIV or hepatitis C virus as well as pathogenic bacteria that are responsible for bacterial vaginosis. Although the antiviral drug, acyclovir, is available, acyclovir needs to be taken as a daily five dose regimen for the duration of symptoms and does not prevent recurring symptoms. There are currently no vaccines available to treat HSV-2, in part due to inherent challenges associated with the development of mucosal vaccines. The goal of our project is to design a new vaccine against HSV-2 by combining the advantages of several existing vaccine platforms. We will test the efficacy in mouse models of vaginal HSV-2 infection. As no successful vaccines are available for HSV-2, our work has the potential to ignite new avenues of research in the development of vaccines against HSV-2.
Competitiondate
202305
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tokuyama, Maria
Approvedterm
1 an 0 mois
Cihrcontribution2
MI #3~ $99,715~ $0~